argenx SE (ARGX)
372.83
+4.23
(+1.15%)
USD |
NASDAQ |
Apr 26, 16:00
372.83
0.00 (0.00%)
After-Hours: 16:56
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 22.11B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -5.61% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 17.38 |
Price to Book Value | 5.396 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 38.20% |
Profile
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
URL | https://www.argenx.com |
Investor Relations URL | https://www.us.argenx.com/investors/stock-information |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Mid Cap/Growth |
Next Earnings Release | May. 09, 2024 |
Last Earnings Release | Feb. 29, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
URL | https://www.argenx.com |
Investor Relations URL | https://www.us.argenx.com/investors/stock-information |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Biotechnology |
Equity Style | Mid Cap/Growth |
Next Earnings Release | May. 09, 2024 |
Last Earnings Release | Feb. 29, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |